메뉴 건너뛰기
JNCCN Journal of the National Comprehensive Cancer Network
Volumn 9, Issue 12, 2011, Pages 1328-1330
Incorporation of crizotinib into the NCCN guidelines
Author keywords

[No Author keywords available]
Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN;
EID: 83755207387     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0113     Document Type: Note
Times cited : (20)
References (9)
  • 2
    • 70349342712 scopus 로고    scopus 로고
    • EML4-ALK: Honing in on a new target in non-small-cell lung cancer
    • Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009;27:4232-4235.
    • (2009) J Clin Oncol , vol.27 , pp. 4232-4235
    • Horn, L.1    Pao, W.2
  • 3
    • 80555139776 scopus 로고    scopus 로고
    • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
    • [abstract]. Abstract CRA7506
    • Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol 2011;29(suppl):Abstract CRA7506.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Kris, M.G.1    Johnson, B.E.2    Kwiatkowski, D.J.3
  • 4
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 5
    • 80054728915 scopus 로고    scopus 로고
    • Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): Profile 1005
    • (O31.05)
    • Riely GJ, Kim DW, Crino L, et al. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): profile 1005. J Thorac Oncol 2011;6:S411(O31.05).
    • (2011) J Thorac Oncol , vol.6
    • Riely, G.J.1    Kim, D.W.2    Crino, L.3
  • 6
    • 37549060017 scopus 로고    scopus 로고
    • EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    • Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
    • (2008) J Thorac Oncol , vol.3 , pp. 13-17
    • Inamura, K.1    Takeuchi, K.2    Togashi, Y.3
  • 7
    • 77149130499 scopus 로고    scopus 로고
    • Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene
    • Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-897.
    • (2010) Ann Surg Oncol , vol.17 , pp. 889-897
    • Takahashi, T.1    Sonobe, M.2    Kobayashi, M.3
  • 8
    • 57349113565 scopus 로고    scopus 로고
    • Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
    • Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
    • (2008) Clin Cancer Res , vol.14 , pp. 6618-6624
    • Takeuchi, K.1    Choi, Y.L.2    Soda, M.3
  • 9
    • 79961099514 scopus 로고    scopus 로고
    • Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    • Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
    • (2011) Am J Surg Pathol , vol.35 , pp. 1226-1234
    • Yoshida, A.1    Tsuta, K.2    Nakamura, H.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.